10033-IM-2 IDENTIFICATION OF THERAPEUTIC TARGET ANTIGENS USING PATIENT DERIVED GLIOBLASTOMA AND THEIR APPLICATION TO CAR-T THERAPY

Hideki Kuroda, Noriyuki Kijima, Tetsuro Tachi, Koki Murakami, Kanji Nakagawa, Yuki Kawamoto, Reina Utsugi, Ryuichi Hirayama, Yoshiko Okita, Naoki Kagawa, Naoki Hosen, Haruhiko Kishima · 2023

Read 10033-IM-2 IDENTIFICATION OF THERAPEUTIC TARGET ANTIGENS USING PATIENT DERIVED GLIOBLASTOMA AND THEIR APPLICATION TO CAR-T THERAPY by Hideki Kuroda, Noriyuki Kijima, Tetsuro Tachi, Koki Murakami, Kanji Nakagawa, Yuki Kawamoto, Reina Utsugi, Ryuichi Hirayama, Yoshiko Okita, Naoki Kagawa, Naoki Hosen, Haruhiko Kishima (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10710575.txt.

Description

Hideki Kuroda and co-authors hunt for new treatment targets in glioblastoma in a 2023 conference abstract. This brain cancer has a poor outlook, and new therapies are badly needed. CAR-T cell therapy is one hopeful path, but past targets gave only limited gains. A target found on tumor cells and not on normal brain cells is key.

The team grows tumor spheres from patient samples and uses them to raise antibodies in mice. About 25,000 antibody strains result. One, called antibody X, reacts with several tumor samples but not with normal brain cells. CAR-T cells built from it show anti-tumor effects in lab tests.

Catalog record

CREATORHideki Kuroda, Noriyuki Kijima, Tetsuro Tachi, Koki Murakami, Kanji Nakagawa, Yuki Kawamoto, Reina Utsugi, Ryuichi Hirayama, Yoshiko Okita, Naoki Kagawa, Naoki Hosen, Haruhiko Kishima
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10710575

Browse the full library · About the Tower of Babel